{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T20:40:02Z","timestamp":1750711202691,"version":"3.41.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T00:00:00Z","timestamp":1720569600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Formosan Medical Association"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.jfma.2024.07.011","type":"journal-article","created":{"date-parts":[[2024,7,14]],"date-time":"2024-07-14T04:41:46Z","timestamp":1720932106000},"page":"628-632","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dynamic changes in \u03b3\u03b4T cells and bone resorption markers after zoledronic acid in multiple myeloma: A prospective study"],"prefix":"10.1016","volume":"124","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4625-0534","authenticated-orcid":false,"given":"Chao-Hung","family":"Wei","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yeu-Chin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shang-Yi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jfma.2024.07.011_bib1","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1084\/jem.20021500","article-title":"Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells","volume":"197","author":"Gober","year":"2003","journal-title":"J Exp Med"},{"issue":"1","key":"10.1016\/j.jfma.2024.07.011_bib2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12967-017-1378-2","article-title":"Gamma-delta (\u03b3\u03b4) T cells: friend or foe in cancer development?","volume":"16","author":"Zhao","year":"2018","journal-title":"J Transl Med"},{"issue":"9","key":"10.1016\/j.jfma.2024.07.011_bib3","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1038\/s41423-020-0504-x","article-title":"Cancer immunotherapy with \u03b3\u03b4 T cells: many paths ahead of us","volume":"17","author":"Kabelitz","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.jfma.2024.07.011_bib4","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.bbrc.2021.12.060","article-title":"Expression level of BTN3A1 on the surface of CD14(+) monocytes is a potential predictor of \u03b3\u03b4 T cell expansion efficiency","volume":"588","author":"Tomogane","year":"2022","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"10.1016\/j.jfma.2024.07.011_bib5","doi-asserted-by":"crossref","first-page":"547","DOI":"10.21873\/anticanres.16191","article-title":"Hypoxia-adapted multiple myeloma stem cells resist \u03b3\u03b4-T-Cell-mediated killing by modulating the mevalonate pathway","volume":"43","author":"Sano","year":"2023","journal-title":"Anticancer Res"},{"key":"10.1016\/j.jfma.2024.07.011_bib6","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.3389\/fimmu.2018.01492","article-title":"V\u03b39V\u03b42 T cells in the bone marrow of myeloma patients: a paradigm of microenvironment-induced immune suppression","volume":"9","author":"Castella","year":"2018","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.jfma.2024.07.011_bib7","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1038\/sj.leu.2403693","article-title":"Effector gammadelta T cells and tumor cells as immune targets of zoledronic acid in multiple myeloma","volume":"19","author":"Mariani","year":"2005","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.jfma.2024.07.011_bib8","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1055\/s-0038-1677483","article-title":"Urinary N-telopeptide: the new diagnostic test for osteoporosis","volume":"5","author":"Ganesan","year":"2019","journal-title":"Surg J"},{"issue":"24","key":"10.1016\/j.jfma.2024.07.011_bib9","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13246212","article-title":"The diverse roles of \u03b3\u03b4 T cells in cancer: from rapid immunity to aggressive lymphoma","volume":"13","author":"Sch\u00f6nefeldt","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.jfma.2024.07.011_bib10","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.3389\/fimmu.2020.02186","article-title":"Pro-tumor \u03b3\u03b4 T cells in human cancer: polarization, mechanisms of action, and implications for therapy","volume":"11","author":"Chabab","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.jfma.2024.07.011_bib11","article-title":"Phase II trial of maintenance treatment with IL2 and zoledronate in multiple myeloma after bone marrow transplantation: biological and clinical results","volume":"11","author":"Fazzi","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.jfma.2024.07.011_bib12","doi-asserted-by":"crossref","first-page":"699","DOI":"10.3389\/fimmu.2020.00699","article-title":"Immune modulation properties of zoledronic acid on TcR\u03b3\u03b4 T-lymphocytes after TcR\u03b1\u03b2\/CD19-depleted haploidentical stem cell transplantation: an analysis on 46 pediatric patients affected by acute leukemia","volume":"11","author":"Merli","year":"2020","journal-title":"Front Immunol"},{"issue":"20","key":"10.1016\/j.jfma.2024.07.011_bib13","doi-asserted-by":"crossref","DOI":"10.3390\/cells12202430","article-title":"Denosumab and zoledronic acid differently affect circulating immune subsets: a possible role in the onset of MRONJ","volume":"12","author":"Roato","year":"2023","journal-title":"Cells"},{"issue":"8","key":"10.1016\/j.jfma.2024.07.011_bib14","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1080\/14653240802419328","article-title":"Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy","volume":"10","author":"Kondo","year":"2008","journal-title":"Cytotherapy"},{"issue":"1","key":"10.1016\/j.jfma.2024.07.011_bib15","doi-asserted-by":"crossref","first-page":"6035","DOI":"10.1038\/s41467-023-41634-7","article-title":"Modulation of lytic molecules restrain serial killing in \u03b3\u03b4 T lymphocytes","volume":"14","author":"Sandoz","year":"2023","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.jfma.2024.07.011_bib16","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/imm.12331","article-title":"Zoledronic acid causes \u03b3\u03b4 T cells to target monocytes and down-modulate inflammatory homing","volume":"143","author":"Fowler","year":"2014","journal-title":"Immunology"},{"key":"10.1016\/j.jfma.2024.07.011_bib17","article-title":"The immune suppressive tumor microenvironment in multiple myeloma: the contribution of myeloid-derived suppressor cells","volume":"13","author":"Giannotta","year":"2022","journal-title":"Front Immunol"},{"issue":"39","key":"10.1016\/j.jfma.2024.07.011_bib18","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000004909","article-title":"In vivo expansion and activation of \u03b3\u03b4 T cells as immunotherapy for refractory neuroblastoma: a phase 1 study","volume":"95","author":"Pressey","year":"2016","journal-title":"Medicine (Baltim)"},{"key":"10.1016\/j.jfma.2024.07.011_bib19","article-title":"The dual roles of human \u03b3\u03b4 T cells: anti-tumor or tumor-promoting","volume":"11","author":"Li","year":"2020","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.jfma.2024.07.011_bib20","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.immuni.2007.05.020","article-title":"Tumor-infiltrating gammadelta T cells suppress T and dendritic cell function via mechanisms controlled by a unique toll-like receptor signaling pathway","volume":"27","author":"Peng","year":"2007","journal-title":"Immunity"},{"key":"10.1016\/j.jfma.2024.07.011_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.915837","article-title":"Gamma delta T-cell based cancer immunotherapy: past-present-future","volume":"13","author":"Saura-Esteller","year":"2022","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.jfma.2024.07.011_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14712598.2022.2147424","article-title":"Where could gammadelta T cells take us in the treatment of cancer?","volume":"23","author":"Corsale","year":"2023","journal-title":"Expet Opin Biol Ther"},{"issue":"1","key":"10.1016\/j.jfma.2024.07.011_bib23","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/s41392-023-01653-8","article-title":"\u03b3\u03b4 T cells: origin and fate, subsets, diseases and immunotherapy","volume":"8","author":"Hu","year":"2023","journal-title":"Signal Transduct Targeted Ther"},{"issue":"2","key":"10.1016\/j.jfma.2024.07.011_bib24","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/CJI.0b013e318245bb1e","article-title":"Tumor-promoting versus tumor-antagonizing roles of \u03b3\u03b4 T cells in cancer immunotherapy: results from a prospective phase I\/II trial","volume":"35","author":"Kunzmann","year":"2012","journal-title":"J Immunother"}],"container-title":["Journal of the Formosan Medical Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664624003140?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664624003140?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T20:13:30Z","timestamp":1750709610000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0929664624003140"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":24,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S0929664624003140"],"URL":"https:\/\/doi.org\/10.1016\/j.jfma.2024.07.011","relation":{},"ISSN":["0929-6646"],"issn-type":[{"type":"print","value":"0929-6646"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dynamic changes in \u03b3\u03b4T cells and bone resorption markers after zoledronic acid in multiple myeloma: A prospective study","name":"articletitle","label":"Article Title"},{"value":"Journal of the Formosan Medical Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfma.2024.07.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Formosan Medical Association. Published by Elsevier Taiwan LLC.","name":"copyright","label":"Copyright"}]}}